MetaCap

Black Hawk Acquisition (BKHA) vs Intensity Therapeutics (INTS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Intensity Therapeutics is the larger company by market cap ($8.2 million vs $7.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BKHA-85.77%INTS-34.74%
+4%-43%-90%
Oct 7, 20261 yearNov 20, 2026
BKHA-83.95%INTS-31.68%
+4%-42%-88%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BKHA versus INTS key metrics
MetricBKHAINTS
Share price$1.85$2.48
Market cap$7.68M$8.19M
1-day change-71.45%-2.36%
YTD return—-75.80%
1-year return—-75.69%
P/E ratio (TTM)5.61—
EPS (TTM)$0.33$-3.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.33M$-11.61M
52-week high$23.00$15.00
52-week low$1.75$2.28
Distance from 52-week high-91.96%-83.47%
Analyst consensus—none
Avg. price target upside—+679.44%
Average volume101.40K22.48K
Shares outstanding4.15M3.30M
Employees—5
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Black Hawk Acquisition

BKHA stock →

Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About Intensity Therapeutics

INTS stock →

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

BKHA vs INTS FAQ

Which is bigger, Black Hawk Acquisition or Intensity Therapeutics?

Intensity Therapeutics (INTS) is larger, with a market capitalization of $8.19M compared with $7.68M for Black Hawk Acquisition (BKHA).

Are Black Hawk Acquisition and Intensity Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons